



### Composition of the 2005–06 Influenza Vaccine

The Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee has recommended that the 2005-06 trivalent influenza vaccine for the United States contain:

- A/New Caledonia/20/99-like (H1N1),
- A/California/7/2004-like (H3N2), and
- B/Shanghai/361/2002-like viruses.

This recommendation was based on antigenic analyses of recently isolated influenza viruses, epidemiologic data, and post-vaccination serologic studies in humans.

Vaccine manufacturers for the United States will use A/New Caledonia/20/99 for the H1N1 component for both the inactivated vaccine (flu shot) and the live attenuated vaccine (nasal spray vaccine).

As of early May, the most likely candidate for the H3N2 component for the flu shot will be the antigenically equivalent strain A/New York/55/2004. For the nasal spray vaccine, vaccine manufacturers for the United States will use A/California/7/2004 for the H3N2 component.

For the B component, vaccine manufacturers for the United States will use the antigenically equivalent strains B/Jiangsu/10/2003 for both the flu shot and the nasal spray vaccine because of its growth properties.

### Related Links

- U.S. Food and Drug Administration ("[Influenza Virus Vaccine](#)")
- World Health Organization ("[Recommendations for Influenza Vaccine Composition](#)")

For more information, visit [www.cdc.gov/flu](http://www.cdc.gov/flu),  
or call CDC at 800-CDC-INFO (English and Spanish) or 888-232-6348 (TTY).